secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047564
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics Q1 net loss $15.4M; workforce cut ~50%; sirexatamab shows positive Phase 2 data
--------------------------------------------------------------------------------

- Net loss of $15.4M in Q1 2025 vs $13.8M in Q1 2024; R&D expense rose to $12.9M.
- Cash and equivalents $32.7M at March 31, 2025.
- Positive DeFianCe study data: 32% higher ORR and 3.5-month PFS benefit in DKK1-high CRC patients.
- Strategic restructuring reduced workforce by ~50% to prioritize sirexatamab and FL-501.
- Engaged financial advisor to explore business development for sirexatamab registrational Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925047564/0001104659-25-047564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925047564/tm2514827d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer